Paul E. Fraser

Toronto, ON, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 88 publications

CD33 and clusterin interact biophysically and genetically to modulate Alzheimer risk.

CD33 and clusterin interact biophysically and genetically to modulate Alzheimer risk.

Journal: Nature communications

Published: February 17, 2026

CD33 and clusterin interact biophysically and genetically to modulate Alzheimer risk.

CD33 and clusterin interact biophysically and genetically to modulate Alzheimer risk.

Journal: Nature communications

Published: February 17, 2026

CD33 and clusterin interact biophysically and genetically to modulate Alzheimer risk.

CD33 and clusterin interact biophysically and genetically to modulate Alzheimer risk.

Journal: bioRxiv : the preprint server for biology

Published: August 06, 2025

The Uppsala APP Mutation Promotes Wild-Type Amyloid-β Aggregation and Deposition In Vivo.

The Uppsala APP Mutation Promotes Wild-Type Amyloid-β Aggregation and Deposition In Vivo.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: July 28, 2025

SUMO-2 activity is inhibited by non-covalent interactions with the Aβ peptide: an exploration of potential pathogenic mechanisms in Alzheimer's disease.

SUMO-2 activity is inhibited by non-covalent interactions with the Aβ peptide: an exploration of potential pathogenic mechanisms in Alzheimer's disease.

Journal: International journal of biological macromolecules

Published: June 05, 2025

A Novel Brain Penetrable Nanocarrier Delivers Brain-Derived Neurotrophic Factor to Treat Alzheimer's Disease.

A Novel Brain Penetrable Nanocarrier Delivers Brain-Derived Neurotrophic Factor to Treat Alzheimer's Disease.

Journal: Advanced healthcare materials

Published: April 08, 2025

Parkinson's disease beyond the brain: implications for treatments.

Parkinson's disease beyond the brain: implications for treatments.

Journal: Frontiers in aging neuroscience

Published: March 26, 2025

Systems-Level Interactome Mapping Reveals Actionable Protein Network Dysregulation Across the Alzheimer's Disease Spectrum.

Systems-Level Interactome Mapping Reveals Actionable Protein Network Dysregulation Across the Alzheimer's Disease Spectrum.

Journal: Research square

Published: February 24, 2025

Appoptosin-Mediated Caspase Cleavage of Tau Contributes to Progressive Supranuclear Palsy Pathogenesis.

Appoptosin-Mediated Caspase Cleavage of Tau Contributes to Progressive Supranuclear Palsy Pathogenesis.

Journal: Neuron

Published: November 09, 2024

Brain microenvironment-remodeling nanomedicine improves cerebral glucose metabolism, mitochondrial activity and synaptic function in a mouse model of Alzheimer's disease.

Brain microenvironment-remodeling nanomedicine improves cerebral glucose metabolism, mitochondrial activity and synaptic function in a mouse model of Alzheimer's disease.

Journal: Biomaterials

Published: August 16, 2024

Genetic and pharmacologic enhancement of SUMO2 conjugation prevents and reverses cognitive impairment and synaptotoxicity in a preclinical model of Alzheimer's disease.

Genetic and pharmacologic enhancement of SUMO2 conjugation prevents and reverses cognitive impairment and synaptotoxicity in a preclinical model of Alzheimer's disease.

Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association

Published: June 18, 2024

Evaluation of the biodistribution and preliminary safety profile of a novel brain-targeted manganese dioxide-based nanotheranostic system for Alzheimer's disease.

Evaluation of the biodistribution and preliminary safety profile of a novel brain-targeted manganese dioxide-based nanotheranostic system for Alzheimer's disease.

Journal: Nanotoxicology

Published: June 07, 2024

Showing 1-12 of 88

Last Updated: 09/26/2026